ACTIVE

RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result278,3 k €+39,7 %over 1 year
Gross margin376 k €+38,5 %over 1 year
Equity771,5 k €+56,4 %over 1 year
Workforce0,0 ETP

Identity

Source · BCE/KBO

RESEARCH, DEVELOPMENT AND SALES FOR MEDECINE is a Public limited company incorporated in 1994. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Hasselt.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0453.323.857
Incorporation
29/08/1994
Legal form
Public limited company
Registered office
Gaarveldstraat 83
3500 Hasselt · FlandreSee on map
Contributed capital
210 446,79 €
Latest accounts
31/12/2025
Average workforce
0,0 ETP
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

Financials

Source · NBB, 20 filings

Trend over 20 financial years

20252024202320222021
Income statement
Gross margin376 k €271,5 k €225,7 k €245,4 k €206,2 k €
EBITDA375,1 k €270,6 k €224,3 k €244 k €204,9 k €
Operating result363,8 k €258,1 k €222,1 k €243,5 k €203,9 k €
Net result278,3 k €199,2 k €165 k €175,1 k €151,8 k €
Balance sheet
Equity771,5 k €493,2 k €594,1 k €429,1 k €254 k €
Total assets856,6 k €890,5 k €671,1 k €587,3 k €446,2 k €
Cash597,4 k €470,1 k €137,3 k €434,8 k €304,6 k €
Debts85,1 k €397,3 k €77,1 k €158,2 k €190,5 k €
Other
Workforce0,0 ETP––––

Valuation

Indicative valuation

As an indication, this company is worth

between 1 M€ and 2,5 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 5 ended

Active mandates

Peter Reyskens

Director · since 15 mars 2004 · until 17 avril 2027

Active
Maria Berghs

Director · since 31 mai 2000 · until 17 avril 2027

Active
Freddy Reyskens

Managing director · since 29 août 1994 · until 17 avril 2027

Active

Ended mandates

Freddy Reyskens

Managing director

Ended
IXSys

Director · 0466.709.164

Represented by Freddy Reyskens

Ended
IXSys nv

Director · 0466.709.164

Represented by Freddy Reyskens

Ended
Maria Berghs

Director

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date08/07/202623/07/202503/07/202423/06/202315/07/202230/06/2021
General meeting18/04/202619/04/202520/04/202422/04/202330/06/202217/04/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 20 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202518/04/202608/07/2026DutchPDF
Abridged model31/12/202419/04/202523/07/2025DutchPDF
Abridged model31/12/202320/04/202403/07/2024DutchPDF
Abridged model31/12/202222/04/202323/06/2023DutchPDF
Abridged model31/12/202130/06/202215/07/2022DutchPDF
Abridged model31/12/202017/04/202130/06/2021DutchPDF
Abridged model31/12/201909/05/202019/06/2020DutchPDF
Abridged model31/12/201820/04/201921/06/2019DutchPDF
Abridged model31/12/201721/04/201803/08/2018DutchPDF
Abridged model31/12/201613/05/201712/07/2017DutchPDF
Abridged model31/12/201530/06/201626/07/2016DutchPDF
Abridged model31/12/201409/05/201520/05/2015DutchPDF
Abridged model31/12/201319/04/201425/04/2014DutchPDF
Abridged model31/12/201211/05/201310/06/2013DutchPDF
Abridged model31/12/201121/04/201218/05/2012DutchPDF
Abridged model31/12/201023/04/201117/05/2011DutchPDF
Abridged model31/12/200917/04/201004/05/2010DutchPDF
Abridged model31/12/200818/04/200928/04/2009DutchPDF
Abridged model31/12/200719/04/200805/05/2008DutchPDF
Abridged model31/12/200621/04/200716/05/2007DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 1 M€ and 2,5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 5 ended

Active mandates

Peter Reyskens

Director · since 15 mars 2004 · until 17 avril 2027

Active
Maria Berghs

Director · since 31 mai 2000 · until 17 avril 2027

Active
Freddy Reyskens

Managing director · since 29 août 1994 · until 17 avril 2027

Active

Ended mandates

Freddy Reyskens

Managing director

Ended
IXSys

Director · 0466.709.164

Represented by Freddy Reyskens

Ended
IXSys nv

Director · 0466.709.164

Represented by Freddy Reyskens

Ended
Maria Berghs

Director

Ended

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates17/02/2023
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Restructuring11/02/2016
    ONTSLAGEN - BENOEMINGEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Restructuring29/09/2015
    RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
    PDF
  • Mandates10/09/2015
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates18/05/2009
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates20/01/2006
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares28/04/2004
    KAPITAAL - AANDELEN - ALGEMENE VERGADERING - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Mandates13/04/2004
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025278,3 k €↑
  2. 2024
    Annual accounts 2024199,2 k €↑
  3. 2023
    Annual accounts 2023165 k €↓
  4. 2022
    Annual accounts 2022175,1 k €↑
  5. 2021
    Annual accounts 2021151,8 k €↑
  6. 2021
    Name changeR.D.S.M.
  7. 2020
    Annual accounts 202068,4 k €↑
  8. 2019
    Annual accounts 20198,7 k €↓
  9. 2018
    Annual accounts 201823,5 k €↑
  10. 2017
    Annual accounts 20175,6 k €↑
  11. 2016
    Annual accounts 20161 k €↓
  12. 2015
    Annual accounts 20156,6 k €↓
  13. 2014
    Annual accounts 201414,8 k €↓
  14. 2013
    Annual accounts 201317,6 k €↑
  15. 2012
    Annual accounts 20129,6 k €↑
  16. 2011
    Annual accounts 20112,2 k €↑
  17. 2010
    Annual accounts 2010-4 k €↑
  18. 2009
    Annual accounts 2009-35,7 k €↓
  19. 2008
    Annual accounts 2008-9,9 k €↓
  20. 2007
    Annual accounts 200723,9 k €↑
  21. 2006
    Annual accounts 200611,3 k €
  22. 2006
    Name changeRESEARCH, DEVELOPMENT AND SALES FOR MEDECINE
  23. 29/08/1994
    IncorporationPublic limited company